Aranidipine (BioDeep_00000648977)
代谢物信息卡片
Aranidipine
化学式: C19H20N2O7 (388.127045)
中文名称: 阿雷地平
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
InChI: InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3
描述信息
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker
C93038 - Cation Channel Blocker
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:31232
- KEGGdrug: D01562
- KEGGdrug: D81791
- PubChem: 2225
- DrugBank: DB09229
- ChEMBL: CHEMBL2104030
- CAS: 86780-90-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Li-rong Yan, Yi-shi Li, Guo-liang Chen, Li Wang, Hui-min Pang, Shi-yao Wu, Jing Yu, Hui-min Li, Ying-zhong Lin, Rui-ping Zhao, Chao-mei Fan. Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial.
Journal of cardiovascular pharmacology.
2012 Jul; 60(1):8-14. doi:
10.1097/fjc.0b013e318254a566. [PMID: 22441301] - Juanjuan Jiang, Lei Tian, Yiling Huang, Yishi Li, Li Xu. Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study.
Clinical therapeutics.
2008 Jul; 30(7):1290-9. doi:
10.1016/s0149-2918(08)80053-7. [PMID: 18691988] - Lei Tian, Juanjuan Jiang, Yiling Huang, Li Xu, Hong Liu, Yishi Li. Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM.
2006; 20(19):2871-7. doi:
10.1002/rcm.2663. [PMID: 16941544] - A Nakamura, K Hayashi, K Fujiwara, Y Ozawa, M Honda, T Saruta. Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection.
Journal of cardiovascular pharmacology.
2000 Jun; 35(6):942-8. doi:
10.1097/00005344-200006000-00018. [PMID: 10836731] - K Ichihara, K Okumura, H Kamei, M Nagasaka, A Kanda, T Kanno, K Miyoshi, H Miyake. Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats.
Journal of cardiovascular pharmacology.
1998 Feb; 31(2):277-85. doi:
10.1097/00005344-199802000-00014. [PMID: 9475270] - M Nakano, K Miyoshi, Y Umeno, K Yoshida, J Nishizaki, H Miyake. Interaction of some drugs on the pharmacokinetics or pharmacodynamics of MPC-1304, a dihydropyridine Ca2+ antagonist.
Archives internationales de pharmacodynamie et de therapie.
1996 Mar; 331(2):109-23. doi:
NULL. [PMID: 8937623] - Y Nozawa, H Miyake, S Yamada, S Uchida, T Ohkura, R Kimura. Receptor occupation and pharmacokinetics of MPC-1304, a new Ca2+ channel antagonist, in spontaneously hypertensive rats.
European journal of pharmacology.
1995 Dec; 287(2):191-6. doi:
10.1016/0014-2999(95)00651-6. [PMID: 8749035] - J Sasaki, G Kajiyama, R Kusukawa, M Shichiri, T Sunaga, H Mashiba, N Tanaka, K Nonaka, K Arakawa. Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
International journal of clinical pharmacology and therapeutics.
1995 Jun; 33(6):366-70. doi:
NULL. [PMID: 7582390] - M Niwa, K Shigematsu, T Maeda, M Fujimoto, K Yamashita, Y Kataoka, K Taniyama. Effects of MPC-1304, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats.
Archives internationales de pharmacodynamie et de therapie.
1994 May; 327(3):309-29. doi:
NULL. [PMID: 7848014] - K Ichihara, K Okumura, H Mori, M Nagasaka. Effects of MPC-1304, a novel Ca2+ entry blocker, on alpha-adrenoceptor-mediated pressor responses in pithed rats.
European journal of pharmacology.
1993 Jul; 238(2-3):283-9. doi:
10.1016/0014-2999(93)90858-f. [PMID: 8104810] - K Miyoshi, A Kanda, H Miyake, K Ichihara, H Kamei, M Nagasaka. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action.
European journal of pharmacology.
1993 Jul; 238(2-3):139-48. doi:
10.1016/0014-2999(93)90841-5. [PMID: 7691619] - A Kanda, A Haruno, K Miyoshi, Y Tanahashi, H Miyake, K Ichihara, K Okumura, M Nagasaka. Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists.
Journal of cardiovascular pharmacology.
1993 Jul; 22(1):167-75. doi:
10.1097/00005344-199307000-00025. [PMID: 7690090] - K Ohashi, T Sudo, K Sakamoto, T Tateishi, A Fujimura, Y Kumagai, T Shiga, A Ebihara. Effect of diltiazem on the pharmacokinetics of MPC-1304, a new calcium channel blocker.
International journal of clinical pharmacology, therapy, and toxicology.
1992 Aug; 30(8):271-4. doi:
NULL. [PMID: 1526689] - Y Iida, Y Kinouchi, Y Takeichi, T Imai, M Otagiri. Simultaneous determination of a new dihydropyridine calcium antagonist (MPC-1304) and its metabolite in dog plasma by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography.
1991 Nov; 571(1-2):277-82. doi:
10.1016/0378-4347(91)80456-m. [PMID: 1810957] - Y Umeno, E Matsushima, M Maniwa, T Marunaka. Gas chromatographic-negative-ion chemical ionization mass spectrometric determination of a new dihydropyridine calcium antagonist (MPC-1304) and its metabolites in human plasma and urine.
Journal of chromatography.
1988 Dec; 434(1):123-33. doi:
10.1016/0378-4347(88)80067-7. [PMID: 3243807]